In ET, the JAK2 V617F mutation is present in approximately 50% of patients and is associated with higher hemoglobin levels, lower platelet counts, elevated leukocyte counts, and increased rates of venous thrombosis compared to ET patients without JAK2 mutations [54]. This evidence concerns the gene JAK2 and essential thrombocythemia.